Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Elicera Therapeutics enters agreement with BioNTech

Elicera Therapeutics’ push to develop novel immuno-oncology therapies just received a significant boost. The company has entered into a collaboration with the German contract development and manufacturing organisation BioNTech for the development of viral vectors to be used in Elicera’s ELC-401 project. Elicera expects to initiate a phase I/II trial with the CAR T-cell candidate in glioblastoma multiforme patients during the second half of 2023.Read the article at biostock.se: https://www.biostock.se/en/2021/11/elicera-therapeutics-enters-agreement-with-biontech/ This is a press

MPC Container Ships ASA announces date for Q3 and nine-month 2021 results

Oslo, 12 November 2021 - MPC Container Ships ASA (the "Company") will be releasing its third quarter 2021 report prior to market opening on Thursday 18 November 2021. The Company will host a webcast for the presentation of the Q3 2021 results commencing on Thursday 18 November 2021 at 15:00 hours CET / 09:00 hours EDT. The presentation will be made available on the Company’s webpage from 12:00 hours CET / 06:00 hours EDT. There will be a Q&A session after the presentation. The event is being streamed. It is recommended that you

Enfo Group’s interim report Q3 July 1 – September 30, 2021

Enfo Q3/2021: Net sales improvedQ3/2021 · Net sales during July–September were EUR 23.1 (21.4) million · EBITDA was EUR 1.9 (1.3) million · Operating profit (EBIT) was EUR -0.3 (-1.0) million · Profit for the period was EUR -0.7 (-1.1) million · Earnings per share were EUR -1.0 (-1.5) · Operating cash flow was EUR -0.7 (1.0) million Q1-Q3/2021 · Net sales during January–September were EUR 76.4 (74.8) million · EBITDA was EUR 5.2 (5.0) million · Operating profit (EBIT) was EUR -2.3 (-1.8) million · Profit for the period was EUR -3.5 (-2.9) million  ·

AZN: Year to date and Q3 2021 results

AstraZeneca PLC 12 November 2021 07:00 GMT Year to date and Q3 2021 results AstraZeneca reinforces its scientific leadership through exceptionalpipeline delivery and the addition of Alexion in the quarter -    Total Revenue in the year to date, including Alexion from 21 July 2021, was $25,406m, representing growth of 32% (28% at CER). Total Revenue in the third quarter increased by 50% (48% at CER) to $9,866m -    Excluding the pandemic COVID-19 vaccine, Total Revenue increased 21% (17% at CER) in the year to date to $23,187m, and by 34% (32% at CER) in the quarter to $8,

North Investment Group AB - Q3 2021

Q3 2021 Interim financial reportFINANCIAL HIGHLIGHTS  · Group revenue of SEK 203.1m (SEK 186.6m). · Gross profit margin 38.6% (38.5%). · EBITDA of SEK 29.8m (SEK 30.2m). · Net operating cash flow SEK 24.7m (SEK 32.5m). · 3PL services in Sweden established with success. · Corporate bond listed on Nasdaq Stockholm 2[nd] November. · Freight prices and raw material prices still on historic high level. · Merge in Sweden finalized 1[st] November. · Order backlog of SEK 138.4m (SEK 85.3m).

Hansa Biopharma Nomination Committee formed

Lund November 12, 2021. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on May 12, 2021 and has the following composition: · Natalie Berner representing Redmile Group · Lotta Sjöberg representing Handelsbanken Fonder  · Jannis Kitsakis representing AP4 As the conveyer of the Nomination Committee, Ulf Wiinberg, Chairman of the Board of Directors at Hansa Biopharma will be asked to summon the first meeting in the Nomination Committee. The function of the Nomination

Remedy Entertainment Plc: Q3 Business Review: Business progressed as planned, outlook unchanged

Remedy Entertainment Plc | Company announcement 09:00 am (EET) 12 November 2021BUSINESS REVIEW January– September 2021 (unaudited) Business progressed as planned, outlook unchanged Alan Wake Remastered announced and completed for launch HIGHLIGHTS IN JULY–SEPTEMBER 2021 · Revenue was 7 398 (9 914) thousand euros and decreased -25.4 % year-on-year primarily due to a decline in Control royalties and reduced development fees from our Smilegate partnership. · Operating profit (EBIT) was 290 (3 443) thousand euros. The decrease was mainly due to a very strong comparison period

K-Fast Holding AB (publ): Interim report January–September 2021

Financial ratios for the period 1 January–30 September 2021     +----------------+---------+---------+---------+---------+--------+|  Financial |    2021 |    2020 |   2021 |    2020 |   2020 ||ratios | Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep |Jan–Dec |+----------------+---------+---------+---------+---------+--------+|  Rental income,| 68.2 | 51.0 | 190.7 |  147.7 |  203.9 ||SEK million | | | | | |+----------------+---------+---------+---------+---------+--------+|  Profit from |  29.8 |  21.2 |

Peab builds nursing home in Oslo

Peab has been commissioned to build the new nursing home Tåsenhjemmet in Oslo. The customer is Oslobygg KF and the contract is worth NOK 446 million.The turnkey contract comprises four floors with 130 private rooms and a daycare center built in solid wood along with a basement. The gross area will be slightly more than 14,000 m2. The new Tåsenhjemmet will be environmentally certified according to BREEAM Excellent and a zero emissions building. The project will also be a so-called FutureBuilt project that promotes climate neutral city development in the Oslo region. “Tåsenhjemmet is a

Sivers Semiconductors AB (publ), Interim Report Q3, January – September 2021

Third quarter 2021 · Revenue amounted to SEK 26.511 M (22.208), an increase of 19% · Profit before depreciation and amortization (EBITDA) amounted to SEK -45.911 M (-38.699) · Operating profit/loss (EBIT) for the period was SEK -53.906 M (-46.030) · Profit/loss after tax was SEK -53.466 M (-151.610) · Earnings per share before and after dilution was SEK -0.34 (-1.07) · Equity per share amounted to SEK 2.75 (2.51) · Profit for the quarter was negatively affected by acquisition costs of SEK 37.371 M relating to the acquisition of MixCommJanuary- September 2021: ·

Kamux Corporation’s Interim Report for January 1 - September 30, 2021

Kamux Corporation                Interim Report                                            November 12, 2021 at 09:00 Kamux Corporation’s Interim Report for January 1 - September 30, 2021 Kamux saw very strong growth, revenue +22.8% - Adjusted operating profit (EBIT) remained below the comparison period The figures in parentheses refer to the comparison period, i.e. the same period in the previous year, unless stated otherwise. July-September in brief - Revenue increased by 22.8%, totaling EUR 254.6 million (207.4) - Gross profit increased by 0.4% to EUR 29.0 million (28.9)

Starbreeze AB (publ) Interim Report Q3 2021

Third quarter 2021 · Net sales amounted to SEK 34.7 million (32.1). PAYDAY accounted for SEK 31.2 million (31.1). · EBITDA* amounted to SEK 19.9 million (11.7). · Amortization, depreciation and impairments amounted to SEK 15.0 million (7.8). · Profit before tax was SEK -8.0 million (-8.2). · Basic and diluted earnings per share was SEK -0.01 (-0.02). Nine-month period 2021 · Net sales amounted to SEK 94.6 million (85.4). PAYDAY accounted for SEK 89.6 million (80.8). · EBITDA* amounted to SEK -9.4 million (44.0). · EBITDA**, adjusted for one-off effects related

The subscription period in Alligator Bioscience's rights issue begins today

Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company") rights issue of shares (the “Rights Issue”) which was resolved by the Board of Directors on 7 October 2021 and approved by the Extraordinary General Meeting held on 8 November 2021. Summary of the Rights Issue · One (1) existing share in the Company entitles to three (3) subscription rights. Two (2) subscription rights entitle to subscription of one (1) new share, i.e., a subscription ratio of 3:2. · The subscription price is SEK 2 per new share, which, assuming

Fortum’s January–September 2021 Interim Report: Strong performance in an exceptional commodity market

FORTUM CORPORATION JANUARY–SEPTEMBER 2021 INTERIM REPORT 12 NOVEMBER 2021 AT 9:00 EET This release is a summary of Fortum’s 2021 January–September 2021 Interim Report. The complete report is attached to this release as a PDF file. It is also available on the company's website at www.fortum.com/investors. July–September 2021 · Comparable EBITDA was EUR 574 (132) million · Comparable operating profit was EUR 260 (-179) million · Operating profit was EUR -3,105 (-1) million, mainly impacted by changes in fair values of non-hedge-accounted derivatives partly offset by capital

Metsä Group very successful in the Finnish Excellence Award 2021 competition

Metsä Group press release 12 November 2021Metsä Board, part of Metsä Group, won the Finnish Excellence Award and the Finnish Circular Economy Award, which was presented for the first time this year. Metsä Spring, Metsä Group’s innovation company, received the Quality Innovation Award for its Kuura textile fibre.  The Excellence and Circular Economy Awards are based on the international EFQM (European Foundation for Quality Management) model, which Metsä Group uses widely in its long-term development. The feedback from internal assessments and from Excellence Award competitions provides

SimCorp reports revenue growth of 8.5% and EBIT margin of 23.2% in 9M 2021

Company Announcement no. 51/2021Q3 2021 highlights: · Reported revenue was EUR 107.3m, an increase of 7.1% when compared with Q3 2020. Measured in local currencies, organic revenue increased by 5.9% when compared with Q3 2020. · EBIT was EUR 24.2m and EBIT margin was 22.6% compared with EBIT of EUR 22.4m and EBIT margin of 22.3% in Q3 2020. · In Q3 2021, two significant transformational SimCorp Dimension license deals were signed with existing clients. The two deals included conversions from perpetual to subscription-based licenses. · Order intake was EUR 27.8m, an increase of

Metsä Board wins prestigious Circular Economy and Quality Award

Metsä Board Corporation press release 12.11.2021Metsä Board, part of Metsä Group, has won both the Finnish Circular Economy Award and the Finnish Quality Award in the Laatukeskus Excellence Finland assessment. The circular economy prize was awarded for the first time this year. Both the Quality Award and the Circular Economy Award are based on the international EFQM (European Foundation for Quality Management) model. The jury of the Circular Economy Award stated that the operations of Metsä Board are clearly outlined, with a systematic approach to defining the company’s direction,

Scandi Standard AB (publ) interim report January - September 2021

Improvement program to address significant challengesJuly – September 2021 · Net sales amounted to MSEK 2,632 (2,621) in the third quarter 2021. At constant exchange rates net sales increased by 1 percent. · Operating income (EBIT) decreased by 74 percent to MSEK 30 (116), corresponding to a margin of 1.1 (4.4) percent. Adjusted operating income (adj. EBIT)[1)] decreased by 71 percent to MSEK 43 (147), corresponding to a margin of 1.6 (5.6) percent. · Income for the period amounted to MSEK 4 (78). Earnings per share amounted to SEK 0.04 (1.21). · Operating cash flow was MSEK

Interim report 1 January – 30 September 2021

Best quarter to dateTHIRD QUARTER 2021 · Revenue increased by 47% to SEK 1,661m (1,129) · Operating profit increased by 37% to SEK 147m (107) · Operating margin decreased to 8.9% (9.5) · The result for the period increased by 34% to SEK 109m (81) · Basic earnings per share amounted to SEK 7.48 (5.57) · Cash flows from operating activities amounted to SEK 327m (100) JANUARY- SEPTEMBER 2021 · Revenue increased by 31% to SEK 4,517m (3,450) · Operating profit increased by 41% to SEK 371m (263) · Operating margin increased to 8.2% (7.6) · The result for the

Adelis Equity Partners Closes EUR 932 million Third Fund

Adelis Equity Partners Fund III has held a final close. The Fund will continue its predecessor funds’ focus on growth-oriented investments in the Nordic mid-market.Adelis Equity Partners Fund III (Adelis III) held a final close on 27 October 2021, following a short period of fundraising. The Fund, which was significantly oversubscribed, raised EUR 855 million from external investors, on top of which Adelis’ employees have committed to invest 9%, or EUR 77 million, for a total fund size of EUR 932 million. Investors in Adelis III include leading pension funds, foundations and fund-of-

Interim report Q3 2021

"The third quarter was another productive period for SynAct Pharma, both from an R&D perspective but also in terms of preparing the company for the intense work ahead and ensuring SynAct is set to take advantage of future opportunities," said Jeppe Øvlesen, CEO.July - September · Net sales during the period amounted to 0 (0) TSEK. · Loss before tax amounted to -20,676 (-9,195) TSEK. · Earnings per share amounted to -0.70 (-0.87) SEK. · Cash flow from operating activities amounted to -18,250 (-8,882) TSEK. · Cash flow from financing activities amounted to 0 (30,806) TSEK.

Kesko’s sales grew in October

Kesko Group's sales totalled €985.7 million in October 2021, representing an increase of 5.0% on the previous year. In comparable terms, sales grew by 3.7%.“Kesko’s sales grew in October thanks to the strong sales performance in building and technical trade,” says Mikko Helander, Kesko’s President and CEO. Sales in the grocery trade division totalled €498.3 million in October, a decrease of 1.2%. Grocery sales to K-food stores decreased by 5.1%, impacted by the fact that in 2020 sales for All Saints' Day fell on October. Sales grew in K-Citymarket’s home and speciality goods trade.

There are no items matching the current filter
There are no more items matching the current filter
Back to top